Companies › Carna Biosciences
1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Sep 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| AS-1763 (docirbrutinib) BTK inhibitor | BTK | Phase 1 | B-cell Malignancy | Sep 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05602363 | AS-1763 (docirbrutinib) | Phase 1 | B-cell Malignancy | Oncology | Sep 2027 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.